Cas No.: | 474645-27-7 |
Chemical Name: | (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1R,2R)-1-Hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohe;[3H]-Vedotin;MMAE;MMAE(Monomethyl Auristain E);MONOMETHYL AURISTATIN E;Vedotin;N-Methyl-L-valyl |
Synonyms: | MMAE, SGD-1010 |
SMILES: | CN[C@H](C(N[C@H](C(N(C([C@@H](CC(N1CCC[C@H]1[C@@H]([C@H](C(N[C@@H]([C@H](C1C=CC=CC=1)O)C)=O)C)OC)=O)OC)[C@H](CC)C)C)=O)C(C)C)=O)C(C)C |
Formula: | C39H67N5O7 |
M.Wt: | 717.97859120369 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Monomethyl auristatin E (MMAE) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. |
In Vivo: | Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPP-cRGD-MMAE with IR produces a more robust and significantly prolongs tumor regression in xenograft models[2]. |
In Vitro: | Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells[1]. MMAE sensitizes colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells[2]. |